saxon-logo-300x73
Book a Demo
saxon-logo-300x73
Contact Us
saxon-logo-300x73
Get Started

Active Pharma Ingredients [API] Change Management in Pharma: Why They Still Take Weeks

API Change Management in Pharma

Share:

Your Active pharma ingredients (API) manufacturer/supplier just changed an analytical method. Small change, they say. Routine improvement. 

Somewhere in your organisation, that notification arrived, probably in a procurement inbox. It got forwarded. Then forwarded again. By the time it reached your regulatory affairs team, a week had already passed without a single assessment being done. 

For API changes, the stakes are higher than most. A specification update, a process adjustment, a new analytical method – any of these can trigger regulatory filing obligations across multiple markets at once.  

The clock starts the moment your supplier makes the change. Your window to assess, classify, and respond is already running, whether your team knows it or not.   

Why the delay compounds at every stage of API change management?

In our regular conversations with multiple regulatory heads and supply chain leaders in pharma industry, we have drilled down to four distinct breakdowns that are interconnected and causing the delay.

Fragmented data

When an Active pharma ingredients manufacturer or supplier’s notification arrives, the information needed to respond like which products use this material, which markets are registered, which dossier sections are affected, is scattered across ERP, QMS, LIMS, and DMS systems that don’t communicate with each other. Before anyone can assess the change, someone has to manually gather that context. That alone takes days.

Manual impact assessment

Even after digitizing QMS, many firms are still depending upon manual impact mapping. So, once the notification reaches the right team, they have to determine what it touches – which products, which markets, what each jurisdiction requires. FDA may require a Prior Approval Supplement. EMA a Type II variation. Certain markets in Southeast Asia may require a submission equivalent to a new drug approval for an API source change. Mapping this manually, dossier by dossier, market by market, turns a two-day exercise into a three-week one.

Have Question ?

We’re here to help!
Get Started

Table of Contents

Approval bottlenecks at every handoff

The notification moves from supplier to procurement to quality to regulatory affairs — each step manually triggered, each dependent on someone noticing, forwarding, and acting. Without automated routing or escalation logic, changes sit in “pending” status when a key stakeholder is unavailable. Nobody has a live view of where a notification is in the process.

Regulatory complexity across markets

Managing differing requirements across FDA, EMA, PMDA, CDSCO, and dozens of other agencies — each with their own classification criteria, timelines, and documentation standards — creates information overload before remediation work even begins. Teams end up reactive, chasing what’s urgent rather than managing what’s strategic. 

These four gaps don’t operate independently. Each one extends the next. A delay in data gathering delays the impact assessment. A delayed assessment delays routing. Delayed routing delays the filing decision. By the time the right person has the full picture, weeks have passed — and the supplier may have already moved to the new process.  

How is AI closing the gap in API Change management?

Intelligence layer across systems

An intelligent layer that integrates across systems like ERP, QMS, LIMS, and DMS brings data together that was previously scattered. When a notification arrives, the full context with details like affected products, registered markets, relevant dossier sections, is already assembled. No data mining. No manual cross-referencing.

AI-driven impact assessment

Agentic AI workflows automatically map incoming Active pharma ingredients change against your approved portfolio, flagging affected products and regulatory filing obligations by market. What currently takes weeks is reduced to days. The regulatory decision stays with your team. The groundwork doesn’t have to.  

Intelligent routing and triage

With rule-based orchestration, agent-driven workflows, and real-time prioritisation, notifications are automatically prioritised by change type and criticality, then routed to the right owner – quality, regulatory affairs, supply chain simultaneously, not sequentially. If a stakeholder is unavailable, the system escalates. Changes don’t sit waiting.
API Change Management in Pharma

Saxon AI's AIssist – Agentic Enterprise AI platform addresses this as an orchestration problem. It comes as an intelligence layer embedded into your existing pharma workflows. By combining enterprise data, governed AI agents, and traceable outputs with full audit trails, it help teams move from fragmented coordination to aligned execution.

Explore AIssist Get a demo

On a closing note

Global regulatory timelines vary by market, and harmonising them is a long-term industry challenge. That part is outside your control. 

But the coordination overhead inside your organisation like fragmented data, manual handoffs, sequential approvals, reactive triage can be fixed. That’s exactly where structured workflow automation and AI for pharma industry can close the gap. 

Saxon AI works with regulatory affairs and supply chain leaders in pharma to automate API change management workflows, from supplier notification through impact assessment to submission coordination. If this is a conversation worth having, we’re ready.  

Let's Connect

FAQs

What is API change management in pharma?
API [Active pharma ingredients] change management is the process pharmaceutical manufacturers follow when an Active Pharmaceutical Ingredient supplier makes a change — to a specification, manufacturing process, analytical method, or facility. The manufacturer must assess the impact of that change on their approved products, determine what regulatory filings are required across each market, and manage the entire workflow from notification to submission. It involves quality, regulatory affairs, supply chain, and procurement teams — and when it runs on manual processes, it consistently takes weeks longer than it should.
The delay rarely has a single cause. It compounds across multiple steps — the notification arrives in the wrong inbox and gets manually forwarded, the impact assessment requires pulling data from disconnected systems, the review involves multiple teams operating sequentially rather than simultaneously, and regulatory requirements differ across every market. Each gap adds days. Together, they add weeks. The problem isn’t that people aren’t working — it’s that the workflow itself isn’t built for speed.
If your team doesn’t respond within the required window, the consequences stack up quickly. The supplier transitions to the new process while your approved dossier still reflects the old one — creating a compliance gap. Regulatory agencies in certain markets may view this as an unapproved change, which can trigger inspection findings, warning letters, or market withdrawal risk. On the supply side, you’re either holding pre-change inventory longer than planned or shipping material against a dossier that no longer matches. Both scenarios are expensive.
AI addresses the coordination-heavy parts of the workflow — the parts where time is lost, not the parts where regulatory judgment is required. Specifically, it connects data across ERP, QMS, LIMS, and DMS systems so teams don’t have to gather context manually. It automatically maps an incoming change against the approved product portfolio to identify what’s affected and in which markets. It routes notifications to the right owners based on change type and priority, rather than relying on manual forwarding. The result is faster detection, faster assessment, and fewer things falling through the gaps — while the regulatory decisions stay with the people qualified to make them.
A supplier change notification (SCN) or supplier-initiated change (SIC) is what your API supplier sends you when they make a change on their end. A post-approval change (PAC) is what you submit to a regulatory agency after you’ve assessed the supplier’s change and determined it affects your approved application. The SCN is the trigger. The PAC is the regulatory response. The gap between the two — how quickly your organisation can move from receiving the notification to submitting the filing — is exactly where most of the delay lives.